We apply complex network theory to analyze the topological properties of DLBCL gene network.
应用复杂网络理论研究DLBCL基因网络的拓扑结构特性。
We studied a series of 16 patients with nodal DLBCL occurring in patients between 10 and 18 years of age.
在此，我们研究了一组少年儿童的结节状DLBCL，患者共16例，年龄介于10至18岁。
This review summarizes the morphological, immunophenotypic, cytogenetic and molecular genetic features of DLBCL relevant to the precise prognostic previsions.
作者综述DLBCL的形态学、免疫组化、分子生物学特点及与预后的关系。
As only 40% of patients benefit from chemotherapy, researchers suspected that DLBCL and other lymphomas could be caused by a variety of cell types gone haywire.
只有40%的病人得益于化疗，研究人员怀疑DLBCL和其它淋巴瘤可能是不同的类型的细胞出问题而形成的。
The project of alternate half-body irradiation combined with R-CHOP to treat DLBCL has effect on apparente synergia and attenuation and could improve the patient's quality of life.
交替半身照射联合美罗华治疗弥漫性大B细胞淋巴瘤有明显的增效、减毒及改善患者生活质量的作用。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
These results demonstrate that CARD11 is a bona fide oncogene in DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
这些结果表明在DLBCL中，CARD11是真正的癌基因，对DLBCL治疗中用药物抑制CARD11通路提供了遗传学理论。
These results demonstrate that CARD11 is a bona fide oncogene in DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.
这些结果表明在DLBCL中，CARD11是真正的癌基因，对DLBCL治疗中用药物抑制CARD11通路提供了遗传学理论。
应用推荐